Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on July 23, 2025
GlobalEdgeMarkets and NetWeb Software in a Live Event: 'AI in Regulated Industry Segments' on July 30, 2025
GlobalEdgeMarkets and NetWeb Software host LinkedIn Live on July 30, 2025, featuring top experts discussing AI in regulated industries. NEW YORK, NY, UNITED STATES, July 23, 2025 /EINPresswire.com/ -- 𝗚𝗹𝗼𝗯𝗮𝗹𝗘𝗱𝗴𝗲𝗠𝗮𝗿𝗸𝗲𝘁𝘀 𝗮𝗻𝗱 𝗡𝗲𝘁𝗪𝗲𝗯 𝗦𝗼𝗳𝘁𝘄𝗮𝗿𝗲 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲 …
Marwood Group Expands Life Sciences & HealthTech Leadership with Appointment of Ex-FDA Policy Leader Dr. Ritu Nalubola
Dr. Nalubola brings 25 years of FDA experience to Marwood, serving most recently as Associate Commissioner and Acting Deputy Commissioner. NEW YORK, NY, UNITED STATES, July 23, 2025 /EINPresswire.com/ -- Marwood Group, a leading healthcare advisory firm …
Grand Madison Acupuncture Now Offering Cosmetic Microneedling with Red Light Therapy
New York-based acupuncture clinic broadens holistic offerings with licensed microneedling and red light therapy for skin rejuvenation. NEW YORK, NY, UNITED STATES, July 23, 2025 /EINPresswire.com/ -- Grand Madison Acupuncture, a renowned wellness center …
Zenzap Introduces GDPR-Compliant Secure Messaging to Help Businesses Protect Their Data
Zenzap helps businesses protect sensitive chats and files with encrypted messaging and full GDPR compliance. NY, UNITED STATES, July 23, 2025 /EINPresswire.com/ -- In an era where business chats often live on personal devices, Zenzap is taking a stand …
Trump and Chronic Venous Insufficiency: A Closer Look at the Condition Affecting Millions
Understand what’s behind President Trump’s CVI diagnosis, what this means and what the possible outcomes can be. NEW YORK, NY, UNITED STATES, July 23, 2025 /EINPresswire.com/ -- Recently, President Donald Trump has been diagnosed with Chronic Venous …
Creative Diagnostics Announces Mammalian HCP ELISA Kits for Biopharmaceutical Research
NEW YORK, NY, UNITED STATES, July 23, 2025 /EINPresswire.com/ -- Creative Diagnostics, a well-known provider of assay kits and services, has announced its Mammalian HCP ELISA Kits. These advanced assay kits can provide sensitive and reliable detection of …
Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025
FREMONT, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. The …
Galapagos versterkt managementteam met ervaren life sciences leidinggevenden om bedrijfstransformatie te versnellen
Benoemt Sooin Kwon tot Chief Business Officer en Dan Grossman tot Chief Strategy Officer Beide leidinggevenden hebben een bewezen staat van dienst op het gebied van strategische uitvoering en het sluiten van deals en zullen helpen bij het stimuleren van …
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation
Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July …
TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference
MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the …
Galapagos verwelkomt ervaren farmaceutische leidinggevenden Dawn Svoronos en Jane Griffiths in haar Raad van Bestuur
Nieuwe Bestuurders brengen uitgebreide commerciële, operationele en transactionele ervaring mee naar de Raad van Bestuur Mechelen, België; 23 juli 2025, 22:01 CET; Galapagos NV (Euronext …
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update
Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive shareholder value and advance pipeline expansion Strategic alternatives for the cell …
Galapagos rapporteert halfjaarcijfers 2025 en geeft een update over de activiteiten in het tweede kwartaal
De benoemingen van een nieuwe CEO, CFO en ervaren business development-leiders met bewezen ervaring in strategische transacties, versterken de positie van het bedrijf om aandeelhouderswaarde te creëren en de pijplijn uit te breiden Strategische …
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
WESTLAKE VILLAGE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report …
LightLife Health Solution Launches Mediterranean-Inspired Wellbeing Programs in South Africa and the USA.
CAPE TOWN, Western Cape, July 23, 2025 (GLOBE NEWSWIRE) -- LightLife Health Solution, a holistic health and nutrition coaching service based in South Africa, has announced the launch of its Mediterranean-inspired wellbeing programs. These structured …
Global Dysmenorrhea Treatment Market to Cross ~USD 8 Billion by 2032 | DelveInsight
New York, USA, July 23, 2025 (GLOBE NEWSWIRE) -- Global Dysmenorrhea Treatment Market to Cross ~USD 8 Billion by 2032 | DelveInsight The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial …
Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports
EXTON, PA, July 23, 2025 (GLOBE NEWSWIRE) -- Biologic use in systemic lupus erythematosus (SLE) is steadily rising, with U.S. rheumatologists now treating close to 40% of their moderate-to-severe patients with biologics. Most expect this number to increase …